🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesType 1.5 diabetes (LADA) and GLP-1 — what worked for you? Page 2

Type 1.5 diabetes (LADA) and GLP-1 — what worked for you?

pete_manc_UK Sun, Mar 16, 2025 at 5:43 AM 36 replies 2,172 viewsPage 2 of 8
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Mar 16, 2025 at 7:53 AM#6
Dr.PainCLE said:
Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction…

My labs after 12 months on glycaemic control: A1C 5.4%, fasting glucose 94 mg/dL, fasting insulin 5 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 8.3% and fasting glucose was 129 mg/dL. The improvement has been dramatic and consistent.

16 11NurseKim_ATL, paul_denver, TinaHashiRN and 13 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Mar 16, 2025 at 8:43 AM#7
pete_manc_UK said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1271059183
Insulin (fasting)2313116
HOMA-IR5.53.81.91.1
Uric Acid8.56.75.84.8

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

15 10tom_AK, josh_phd_bmore, roxy_nash and 12 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Mar 16, 2025 at 9:33 AM#8
LarryQC_SD said:
My labs after 12 months on glycaemic control: A1C 5.4%, fasting glucose 94 mg/dL, fasting insulin 5 uIU/mL.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 20%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

14 9marcus_mpls, DeniseRN_TPA, SandraNC_45 and 11 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
tony_orlando
Member
234
1,123
Nov 2024
Orlando, FL
Mar 16, 2025 at 10:23 AM#9

One thing that is still open after jim_asheville’s answer:

What did you change at the same time, and can you separate the two now?

13 8CanadaChris, ZaraB_AL, JakeSmashed95 and 10 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Mar 16, 2025 at 2:23 PM#10
Dr.EndoIndy said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 20%.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

21 19mike.trainer_LA, sarah_nash92, FitDadDave and 18 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register